Study of Pharmacokinetics, Efficacy, and Safety of a Recombinant and Protein-Free Factor VIII (rAHF-PFM) in Pediatric Patients With Hemophilia A

Inclusion criteria

• Subject is less than 6 years of age
• Severe or moderately-severe hemophilia A as defined by a baseline factor VIII level <= 2%, documented at screening or on the basis of historical data (e.g., at hemophilia diagnosis)
• Documented medical history of at least 50 exposure days for treatment with all other factor VIII products
• Subject's parent or legally authorized representative has provided informed consent

Exclusion criteria

• Detectable inhibitor to factor VIII measured in the screening sample by the local or central hemostasis laboratory
• History of inhibitor to factor VIII at any time prior to screening
• Subject has any one of the following laboratory abnormalities at the time of screening:

• platelet count < 100,000/mm3
• hemoglobin concentration < 10 g/dL (100 g/L)
• serum creatinine > 1.5 times the ULN for age
• total bilirubin > 2 times the ULN for age
• Subject has an inherited or acquired hemostatic defect other than hemophilia A (e.g., platelet dysfunction secondary to uremia, liver failure, von Willebrand's Disease)
• Subject has known hypersensitivity to RECOMBINATE rAHF
• Subject is currently participating in another investigational drug study or has participated in any clinical study involving an investigational drug within 30 days of study entry
• Subject is identified by the investigator as being unable or unwilling to cooperate with study procedures